BD Announces First Phasix™ Hernia Prevention Case in Greece

BD (Becton, Dickinson and Company) has announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product’s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.

The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix™ Mesh (08 x 30 cm) was placed prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.

Concurrently, BD’s PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated over 85% of its target population and is projected to complete enrollment in 2026. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting PMA submission for an incisional hernia prevention indication in the United States.

“Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually,” said Rian Seger, worldwide president of the BD Surgery business. “With Phasix™ Mesh, we’re not just repairing hernias—we’re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.”

According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of £23,148—nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.

Phasix™ Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the U.K. and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. Phasix™ Mesh is not indicated for use for hernia prevention in the United States.

Source: BD (Becton, Dickinson and Company)

The post BD Announces First Phasix™ Hernia Prevention Case in Greece appeared first on Surgical Robotics Technology.